CD274 and non-small cell lung carcinoma: A recent phase II study also indicated that dual PD-L1/TIGIT blockade (atezolizumab/tiragolumab) has superior clinical benefits compared to PD-L1 blockade alone in NSCLC patients, despite similar profiles of toxicity and tolerability (137).